RxDoctor Payments Data

John Manis, MD

Hematology & Oncology · Boston, MANPI 1720072424

Payments from drug & device makers

$66,138in general payments, 2019–2025

Across 34 payments — averaging $1945.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$40K
  • Sanofi US Services Inc.$11K
  • Gamida Cell Inc.$11K
  • Terumo BCT, Inc.$4K
  • Genetix Biotherapeutics Inc$419
  • Werfen USA LLC$56

What the payments were for

  • Consulting fees$48,23573%
  • Speaking & faculty fees$13,86821%
  • Travel & lodging$2,9714%
  • Food & beverage$9972%
  • Education$680%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex19$40,305
Sanofi US Services Inc.1$11,074
Gamida Cell Inc.1$10,500
Terumo BCT, Inc.10$3,785
Genetix Biotherapeutics Inc2$419
Werfen USA LLC1$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,138 in reported general payments places this provider in the 60th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$5,896
Medicare patients
45
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →